PL2635604T3 - Kompozycja przeciwciała PAN-HER - Google Patents

Kompozycja przeciwciała PAN-HER

Info

Publication number
PL2635604T3
PL2635604T3 PL11797354T PL11797354T PL2635604T3 PL 2635604 T3 PL2635604 T3 PL 2635604T3 PL 11797354 T PL11797354 T PL 11797354T PL 11797354 T PL11797354 T PL 11797354T PL 2635604 T3 PL2635604 T3 PL 2635604T3
Authority
PL
Poland
Prior art keywords
pan
antibody composition
antibody
composition
Prior art date
Application number
PL11797354T
Other languages
English (en)
Polish (pl)
Inventor
Mikkel Wandahl Pedersen
Ida K. Christensen
Johan Lantto
Helle Jacobsen
Michael Kragh
Original Assignee
Symphogen A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symphogen A/S filed Critical Symphogen A/S
Publication of PL2635604T3 publication Critical patent/PL2635604T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL11797354T 2010-11-01 2011-10-31 Kompozycja przeciwciała PAN-HER PL2635604T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40878210P 2010-11-01 2010-11-01
DKPA201000988 2010-11-01
DKPA201100672 2011-09-05
US201161531407P 2011-09-06 2011-09-06

Publications (1)

Publication Number Publication Date
PL2635604T3 true PL2635604T3 (pl) 2017-09-29

Family

ID=59014867

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11797354T PL2635604T3 (pl) 2010-11-01 2011-10-31 Kompozycja przeciwciała PAN-HER

Country Status (13)

Country Link
US (1) US9217039B2 (cg-RX-API-DMAC7.html)
EP (3) EP2635604B1 (cg-RX-API-DMAC7.html)
JP (2) JP6186277B2 (cg-RX-API-DMAC7.html)
KR (2) KR101862832B1 (cg-RX-API-DMAC7.html)
AU (2) AU2011324870B2 (cg-RX-API-DMAC7.html)
CA (2) CA2816520C (cg-RX-API-DMAC7.html)
DK (1) DK2635604T3 (cg-RX-API-DMAC7.html)
ES (2) ES2692379T3 (cg-RX-API-DMAC7.html)
IL (2) IL225953A0 (cg-RX-API-DMAC7.html)
MX (2) MX347981B (cg-RX-API-DMAC7.html)
PL (1) PL2635604T3 (cg-RX-API-DMAC7.html)
TW (1) TW201231066A (cg-RX-API-DMAC7.html)
WO (2) WO2012059858A1 (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010022736A2 (en) * 2008-08-29 2010-03-04 Symphogen A/S Recombinant anti-epidermal growth factor receptor antibody compositions
US8883149B2 (en) 2008-09-15 2014-11-11 Yeda Research And Development Co. Ltd. Antibody combinations and use of same for treating cancer
NZ600262A (en) 2009-12-22 2013-06-28 Roche Glycart Ag Anti-her3 antibodies and uses thereof
MX347981B (es) 2010-11-01 2017-05-22 Symphogen As Composicion de anticuerpos pan-her.
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
US20150231238A1 (en) * 2011-03-15 2015-08-20 Merrimack Pharmaceuticals, Inc. Overcoming resistance to erbb pathway inhibitors
US9040047B2 (en) 2011-05-16 2015-05-26 Yeda Research And Development Co. Ltd. Combinations of anti ErbB antibodies for the treatment of cancer
LT2837680T (lt) * 2011-07-01 2020-07-10 Amgen Inc. Žinduolių ląstelių kultūra
WO2013078191A1 (en) 2011-11-23 2013-05-30 Medimmune, Llc Binding molecules specific for her3 and uses thereof
RU2014136886A (ru) * 2012-03-27 2016-05-20 Дженентек, Инк. Диагностика и виды лечения, связанные с ингибиторами her3
KR101933990B1 (ko) 2012-05-02 2018-12-31 심포젠 에이/에스 인간화 ｐａｎ­ｈｅｒ 항체 조성물
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
US10081681B2 (en) 2013-09-20 2018-09-25 Bristol-Myers Squibb Company Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors
US11305012B2 (en) 2013-09-24 2022-04-19 Medimmune, Llc Binding molecules specific for HER3 and uses thereof
US10745490B2 (en) 2014-04-11 2020-08-18 Celldex Therapeutics, Inc. Anti-ErbB antibodies and methods of use thereof
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US10526416B2 (en) 2014-09-08 2020-01-07 Yeda Research And Development Co. Ltd. Anti-HER3 antibodies and uses of same
JP2017534574A (ja) 2014-09-08 2017-11-24 イェダ リサーチ アンド ディベロップメント カンパニー リミテッドＹｅｄａ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏ．Ｌｔｄ． チロシンキナーゼ阻害薬（ｔｋｉ）に耐性のがんを処置するための組成物および方法
AU2015316522B2 (en) 2014-09-16 2021-01-21 Symphogen A/S Anti-met antibodies and compositions
EP3176183A1 (en) 2015-12-02 2017-06-07 Yeda Research and Development Co. Ltd Compositions and methods for treating cancer not resistant to a tyrosine kinase inhibitor (tki)
MA43416A (fr) 2015-12-11 2018-10-17 Regeneron Pharma Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
JP7088454B2 (ja) 2015-12-30 2022-06-21 コディアック サイエンシーズ インコーポレイテッド 抗体および抗体複合体
WO2017194554A1 (en) 2016-05-10 2017-11-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations therapies for the treatment of cancer
WO2018185232A1 (en) 2017-04-05 2018-10-11 Symphogen A/S Combination therapies targeting pd-1, tim-3, and lag-3
IL322104A (en) 2017-05-30 2025-09-01 Bristol Myers Squibb Co Treatment of lag-3 positive tumors
WO2018222722A2 (en) 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
JP7654539B2 (ja) * 2018-09-07 2025-04-01 ファイザー・インク 抗αｖβ８抗体、組成物及びその使用
MA54944A (fr) * 2019-02-14 2021-12-22 Merus Nv Combinaisons de fractions de liaison se liant à egfr, her2 et her3
CN114426578B (zh) * 2019-02-14 2025-03-21 美勒斯公司 结合egfr、her2及her3的结合部分的组合
US20220259290A1 (en) * 2019-07-24 2022-08-18 Japan Science And Technology Agency Innovative production technique for antibody-enzyme
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
JP7623497B2 (ja) 2020-12-31 2025-01-28 サノフイ ＮＫｐ４６およびＣＤ１２３に結合する多機能性ナチュラルキラー（ＮＫ）細胞エンゲージャ
CN119365495A (zh) 2022-05-27 2025-01-24 赛诺菲 与NKp46和BCMA变体结合的具有Fc工程化的自然杀伤（NK）细胞接合物
TW202500584A (zh) 2023-05-19 2025-01-01 法商施維雅藥廠 抗met抗體、抗體-藥物結合物、組合物及其用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968511A (en) * 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
PT896586E (pt) * 1996-03-27 2007-01-31 Genentech Inc Anticorpos de erbb3
AUPQ105799A0 (en) * 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
MXPA02010011A (es) 2000-04-11 2003-04-25 Genentech Inc Anticuerpos multivalentes y usos para los mismos.
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
EA013225B1 (ru) 2003-01-07 2010-04-30 Симфоген А/С Способ получения линии клеток, продуцирующей рекомбинантный поликлональный белок, способ получения поликлонального белка, линия клеток, продуцирующая рекомбинантный поликлональный белок, библиотека векторов, популяция клеток
US20070003556A1 (en) * 2003-03-31 2007-01-04 Masayuki Tsuchiya Modified antibodies against cd22 and utilization thereof
TWI333977B (en) 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
EP2053408B1 (en) 2004-07-20 2012-03-07 Symphogen A/S A procedure for structural characterization of a recombinant polyclonal protein or a polyclonal cell line
ZA200701234B (en) 2004-07-22 2008-12-31 Genentech Inc HER2 antibody composition
JP2008523073A (ja) 2004-12-07 2008-07-03 ジェネンテック・インコーポレーテッド Ｈｅｒ阻害剤を用いた治療のための患者の選択
AR056857A1 (es) * 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
WO2008031531A1 (en) * 2006-09-15 2008-03-20 F. Hoffmann-La Roche Ag Tumor therapy with a combination of anti-her2 antibodies
KR101598229B1 (ko) * 2007-02-16 2016-02-26 메리맥 파마슈티컬즈, 인크. Ｅｒｂｂ3에 대한 항체 및 이의 용도
DK2132229T3 (en) 2007-03-01 2016-06-20 Symphogen As Recombinant anti-epidermal growth factor receptor-ANTIBODY COMPOSITIONS
EP2152872B1 (en) 2007-05-25 2010-09-15 Symphogen A/S Method for manufacturing a recombinant polyclonal protein
JP2011522213A (ja) 2007-11-22 2011-07-28 シムフォゲン・アクティーゼルスカブ 組み換えポリクローナルタンパク質の特徴づけに関する方法
WO2009129814A1 (en) 2008-04-23 2009-10-29 Symphogen A/S Methods for manufacturing a polyclonal protein
AU2009281721A1 (en) 2008-08-15 2010-02-18 Merrimack Pharmaceuticals, Inc. Methods and systems for predicting response of cells to a therapeutic agent
WO2010022736A2 (en) * 2008-08-29 2010-03-04 Symphogen A/S Recombinant anti-epidermal growth factor receptor antibody compositions
WO2010040356A1 (en) 2008-10-06 2010-04-15 Symphogen A/S Method for identifying and selecting drug candidates for combinatorial drug products
NZ594665A (en) * 2009-03-20 2013-08-30 Genentech Inc Bispecific anti-her antibodies
ES2537100T3 (es) * 2009-04-07 2015-06-02 Roche Glycart Ag Anticuerpos biespecíficos trivalentes
PE20120550A1 (es) * 2009-04-07 2012-05-21 Roche Glycart Ag ANTICUERPOS BIESPECIFICOS ANTI-ErbB-3/ANTI-C-MET
US8362215B2 (en) 2009-04-29 2013-01-29 Trellis Bioscience, Llc Antibodies immunoreactive with heregulin-coupled HER3
CA2766608C (en) 2009-07-06 2018-06-19 F. Hoffmann-La Roche Ag Bi-specific digoxigenin binding antibodies
CA2771744A1 (en) * 2009-08-21 2011-02-24 Merrimack Pharmaceuticals, Inc. Antibodies against the ectodomain of erbb3 and uses thereof
EP2486052A4 (en) 2009-10-09 2013-05-01 Merck Sharp & Dohme GENERATION, LABELING AND USE OF ANTI-HER3 ANTIBODIES
PL2719708T3 (pl) 2009-11-13 2018-04-30 Daiichi Sankyo Europe Gmbh Materiał i sposoby leczenia lub zapobiegania chorobom związanym z HER-3
EP2542589A4 (en) * 2010-03-04 2013-08-07 Symphogen As ANTIBODIES AND COMPOSITIONS ANTI-HER2
US8481687B2 (en) * 2010-04-09 2013-07-09 Aveo Pharmaceuticals, Inc. Anti-ErbB3 antibodies
PH12013500333A1 (en) * 2010-08-20 2013-04-22 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
MX347981B (es) 2010-11-01 2017-05-22 Symphogen As Composicion de anticuerpos pan-her.

Also Published As

Publication number Publication date
AU2011324870A1 (en) 2013-01-31
MX2013004897A (es) 2013-07-15
US9217039B2 (en) 2015-12-22
MX348637B (es) 2017-06-22
CA2816520A1 (en) 2012-05-10
JP6033783B2 (ja) 2016-11-30
KR101862832B1 (ko) 2018-05-30
KR20140026336A (ko) 2014-03-05
AU2011324870B2 (en) 2015-01-29
AU2011324871A1 (en) 2013-05-09
US20130287684A1 (en) 2013-10-31
EP2635604B1 (en) 2016-11-30
JP2014503189A (ja) 2014-02-13
KR101773120B1 (ko) 2017-08-30
CA2816520C (en) 2017-11-21
EP2635605B1 (en) 2018-07-25
ES2616961T3 (es) 2017-06-14
EP2635604A2 (en) 2013-09-11
KR20140026337A (ko) 2014-03-05
CA2816519A1 (en) 2012-05-10
EP3156421A1 (en) 2017-04-19
IL225954A0 (en) 2013-07-31
IL225953A0 (en) 2013-07-31
JP6186277B2 (ja) 2017-08-23
MX2013004899A (es) 2013-07-15
WO2012059858A1 (en) 2012-05-10
CA2816519C (en) 2019-01-15
EP2635605A1 (en) 2013-09-11
JP2014503188A (ja) 2014-02-13
EP3156421B1 (en) 2018-06-06
DK2635604T3 (en) 2017-02-27
TW201231066A (en) 2012-08-01
ES2692379T3 (es) 2018-12-03
WO2012059857A2 (en) 2012-05-10
AU2011324871B2 (en) 2016-05-19
EP2635605A4 (en) 2014-10-22
WO2012059857A3 (en) 2012-07-19
MX347981B (es) 2017-05-22
IL225954B (en) 2018-05-31

Similar Documents

Publication Publication Date Title
IL225953A0 (en) An antidote–her@@pan
HUS1900020I1 (hu) CGRP ellenanyagok
HUE040213T2 (hu) Anti-TIM antitest
PL3342786T3 (pl) Przeciwciało przeciwko dll3
PL2616489T3 (pl) Przeciwciało anty-huTNFR1
DK3904391T3 (en) Monoclonal antibodies against c-met
ZA201209004B (en) Anti-fgfr2 antibodies
GB201000467D0 (en) Antibodies
IL223366B (en) antibody against cmet
IL221371A0 (en) Anti-lrp6 antibodies
IL226113A0 (en) combinations of met–c antibodies
IL222374A (en) Antiviral cleanser
PT2603528T (pt) Anticorpos glicosilados em fab
SI2636736T1 (sl) Novo anti-dr5 protitelesce
GB201020738D0 (en) Antibodies
ZA201302459B (en) Antibodies
GB201002238D0 (en) Antibodies
EP2588141A4 (en) ANTIBODY FORMULATIONS
ZA201300804B (en) Anti-vegfr-3 antibody compositions
GB201007957D0 (en) Antibody
GB201017780D0 (en) Antibody
GB201020751D0 (en) Antibodies
GB201005062D0 (en) Antibodies